Английская Википедия:Ibrexafungerp
Шаблон:Short description Шаблон:Use American English Шаблон:Use dmy dates Шаблон:Infobox drug
Ibrexafungerp, sold under the brand name Brexafemme, is an antifungal medication used to treat vulvovaginal candidiasis (VVC) (vaginal yeast infection).[1] It is taken orally (by mouth).[1] It is also currently undergoing clinical trials for other indications via an intravenous (IV) formulation. An estimated 75% of women will have at least one episode of VVC and 40 to 45% will have two or more episodes in their lifetime.[2]
Ibrexafungerp acts via inhibition of glucan synthase, which prevents formation of the fungal cell wall.[1]
Ibrexafungerp was approved for medical use in the United States in June 2021.[1][3] It is the first non-azole oral antifungal drug to be approved by the U.S. Food and Drug Administration (FDA) for the treatment of vaginal yeast infections.[3] The FDA considers it to be a first-in-class medication.[4]
Medical uses
Ibrexafungerp is indicated for the treatment of adult and postmenarchal pediatric females with vulvovaginal candidiasis (VVC).[1][3]
Ibrexafungerp is currently undergoing late-stage clinical trials for an intravenous formulation for the treatment of various fungal diseases, including life-threatening fungal infections caused primarily by Candida (including C. auris) and Aspergillus species. It has demonstrated broad-spectrum antifungal activity, in vitro and in vivo, against multidrug-resistant pathogens, including azole- and echinocandin-resistant strains.[5]
Pharmacology
Pharmacodynamics
Ibrexafungerp is a triterpenoid antifungal agent.[1] It acts via inhibition of the enzyme glucan synthase, which is involved in the formation of 1,3-β-D-glucan—an essential component of the fungal cell wall.[1] The compound has concentration-dependent fungicidal activity against Candida species.[1]
Pharmacokinetics
Ibrexafungerp has a time to maximal concentrations of 4 to 6Шаблон:Nbsphours.[1] It is metabolized by hydroxylation via CYP3A4 and subsequently by glucuronidation and sulfation.[1] The medication has an elimination half-life of approximately 20Шаблон:Nbsphours.[1]
Synthesis
References
Further reading
External links
Шаблон:Antifungals Шаблон:Portal bar
Шаблон:Antiinfective-drug-stub
- ↑ 1,00 1,01 1,02 1,03 1,04 1,05 1,06 1,07 1,08 1,09 1,10 Ошибка цитирования Неверный тег
<ref>; для сносокBrexafemme FDA labelне указан текст - ↑ Шаблон:Cite web
- ↑ 3,0 3,1 3,2 Шаблон:Cite press release
- ↑ Шаблон:Cite report Шаблон:PD-notice
- ↑ Шаблон:Cite web
- ↑ Шаблон:Cite journal
- Английская Википедия
- Страницы с неработающими файловыми ссылками
- Amino acids
- Antifungals
- Heterocyclic compounds with 5 rings
- Oxygen heterocycles
- 4-Pyridyl compounds
- Triazoles
- Страницы, где используется шаблон "Навигационная таблица/Телепорт"
- Страницы с телепортом
- Википедия
- Статья из Википедии
- Статья из Английской Википедии
- Страницы с ошибками в примечаниях
